Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines

Maria Cosenza, Monica Civallero, Steven N Quayle, Stefano Sacchi, Samantha Pozzi

Blood (2016) 128 (22): 2772.

https://doi.org/10.1182/blood.V128.22.2772.2772

Published: 2016

Journal Articles

Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model

Kamira Karen Maharaj, BS, John J. Powers, B.S., Susan Deng, BS, Alex Achille, BS, Mibel Pabon-Saldana, Renee Fonseca, Steven N Quayle, Simon S Jones, PhD, Eva Sahakian, PhD, Javier Pinilla-Ibarz, MD PhD

Blood (2016) 128 (22): 2035.

https://doi.org/10.1182/blood.V128.22.2035.2035

Published: 2016

Journal Articles

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

Ruben Niesvizky, MD, Paul G. Richardson, MD, Nashat Y. Gabrail, MD, Sumit Madan, MD, Andrew J. Yee, MD, Steven N Quayle, PhD, Ingrid Almeciga-Pinto, PhD, Simon S Jones, PhD, Lee Houston, Denise Hayes, John Van Duzer, PhD, Catherine Wheeler, MD, Nikolaus S. Trede, MD PhD, Noopur S. Raje, MD

Blood (2015) 126 (23): 3040.

https://doi.org/10.1182/blood.V126.23.3040.3040

Published: 2015

Journal Articles

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Fengdong Cheng, MD, Bing Xia, MD, Eva Sahakian, PhD, Tint Lwin, MD PhD, Hongwei Wang, MD, Limin Xing, MD, Bijal D. Shah, MD, Patricio PerezVillarroel, BS, Maritza LienlafMoreno, BS, Yizhuo Zhang, MD, Steven N Quayle, PhD, Simon S Jones, PhD, Javier Pinilla-Ibarz, MD PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 5397.

https://doi.org/10.1182/blood.V124.21.5397.5397

Published: 2014

Journal Articles

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

Allison J Berger, PhD, Bret Bannerman, Steven N Quayle, PhD, Jie Yu, Khristofer Garcia, Jeffrey Ciavarri, PhD, David Tamang, PhD, Min Yang, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 4437.

https://doi.org/10.1182/blood.V122.21.4437.4437

Published: 2013

Journal Articles

ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM)

Steven N Quayle, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 1952.

https://doi.org/10.1182/blood.V122.21.1952.1952

Published: 2013

Journal Articles

Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells

Steven N Quayle, PhD, David Tamang, PhD, Min Yang, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 3071.

https://doi.org/10.1182/blood.V122.21.3071.3071

Published: 2013

NARROW

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines

Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM)

Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells

Email alerts

ASH Publications

American Society of Hematology

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines

Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM)

Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only